AMPLIFY-201 Phase I Trial
![ASCO 2023: Elicio Therapeutics Unveils Promising Interim Results from AMPLIFY-201 Phase I Trial of Cutting-Edge Cancer Immunotherapy.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Elicio-Therapeutics-Unveils-Promising-Interim-Results-from-AMPLIFY-201-Phase-I-Trial-of-Cutting-Edge-Cancer-Immunotherapy.jpg)
ASCO 2023: Elicio Therapeutics Unveils Promising Interim Results from AMPLIFY-201 Phase I Trial of Cutting-Edge Cancer Immunotherapy
SG Tylor
ABSTRACT NUMBER – 2528 ELI-002 represents a new therapeutic vaccine called AMP that specifically targets KRAS-driven cancers. KRAS mutations are ...